References
- Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
- Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 2000–2004. 2008.
- Kogevinas M, Porta M. Socioeconomic differences in cancer survival: a review of the evidence. IARC Sci Publ 1997;138: 177–206.
- Woods LM, Rachet B, Coleman MP. Origins of socioeconomic inequalities in cancer survival: a review. Ann Oncol 2006;17: 5–19.
- Hanlon P, Walsh D, Buchanan D, et al. Chasing the Scottish Effect: Why Scotland Needs a Step-change in Health if it is to Catch Up with the Rest of Europe. Glasgow: Public Health Institute of Scotland; 2001
- Leon DA, Morton S, Cannegieter S, McKee M. Understanding the Health of Scotland's Population in an International Context: A Review of Current Approaches, Knowledge and Recommendations for New Research Direction. Glasgow: Public Health Institute of Scotland; 2003
- Carstairs V, Morris R. Deprivation: explaining differences in mortality between Scotland and England and Wales. BMJ 1989;299:886–9.
- News.bbc.co.uk. 2002 [updated 18 Feb 2002; cited 30 April 2013]. Available from: http://news.bbc.co.uk/1/hi/uk/1826411.stm
- News.bbc.co.uk. 2003 [updated 27 Feb 2003; cited 30 April 2013]. Available from:” http://news.bbc.co.uk/go/pr/fr/-/1/hi/scotland/2804895.stm
- The Centre for Social Justice. Breakthrough Glasgow: Ending the Costs of Social Breakdown. London: Centre for Social Justice, 2008
- Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiformed treated with combined modality approach. J Cancer Res Clin Oncol 2003;129:477–84.
- Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.
- Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry 2011;82:441–6.
- Dunn J, Barborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolamide and radiotherapy. Br J Cancer 2009;101:124–31.
- Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in the elderly people – a randomised study. Acta Neurochir (Wien) 2003;145:5–10.
- Stummer W, Reulen HJ, Meiner T, et al.; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62:564–76.
- Stummer W, Pichlmeier U, Meinel T, et al.; ALA-Glioma Study Group. Fluoresecence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392–401.
- Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3–8.
- Sperduto CM, Chakravarti A, Aldape K, et al. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys 2009;75:1162–5.